Ken Shain, MD, PhD, spoke about the dramatic impact of novel immunotherapies in the multiple myeloma treatment landscape, as well as other updates from the 2022 ASH Annual Meeting and Exposition.
Transcript:
Immunotherapies—meaning bispecifics and CAR T—are going to change the way we take care of our disease. We need to figure out how to make sure all patients will have access to these novel therapies, these novel immunotherapies, or these T cell–engaging therapies. We’re on the horizon of understanding what they mean clinically, and how they work in the context of the immune microenvironment.
Transcript edited for clarity.
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings
August 27th 2024Strategies for treating patients with multiple myeloma who are eligible to receive CAR T-cell therapy in either community or academic practices were discussed in a recent Training Academy.